nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—SLC22A5—Organic cation transport—SLC22A3—prostate cancer	0.00575	0.0888	CbGpPWpGaD
Ceftazidime—SLC22A5—Organic cation transport—SLC22A1—prostate cancer	0.00469	0.0724	CbGpPWpGaD
Ceftazidime—SLC22A5—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.0039	0.0603	CbGpPWpGaD
Ceftazidime—SLC22A5—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.00318	0.0491	CbGpPWpGaD
Ceftazidime—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.00294	0.0455	CbGpPWpGaD
Ceftazidime—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.0029	0.0448	CbGpPWpGaD
Ceftazidime—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.00269	0.0416	CbGpPWpGaD
Ceftazidime—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.0024	0.0371	CbGpPWpGaD
Ceftazidime—SLC15A1—epithelium—prostate cancer	0.00197	0.122	CbGeAlD
Ceftazidime—SLC15A1—renal system—prostate cancer	0.00183	0.113	CbGeAlD
Ceftazidime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.00171	0.0264	CbGpPWpGaD
Ceftazidime—SLC15A2—prostate gland—prostate cancer	0.00168	0.103	CbGeAlD
Ceftazidime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.00159	0.0245	CbGpPWpGaD
Ceftazidime—SLC22A5—prostate gland—prostate cancer	0.00146	0.09	CbGeAlD
Ceftazidime—SLC15A2—seminal vesicle—prostate cancer	0.00142	0.0875	CbGeAlD
Ceftazidime—SLC22A5—seminal vesicle—prostate cancer	0.00123	0.0761	CbGeAlD
Ceftazidime—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.00121	0.0187	CbGpPWpGaD
Ceftazidime—SLC15A2—renal system—prostate cancer	0.00114	0.0705	CbGeAlD
Ceftazidime—SLC15A2—urethra—prostate cancer	0.00112	0.0693	CbGeAlD
Ceftazidime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.00107	0.0166	CbGpPWpGaD
Ceftazidime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.00107	0.0166	CbGpPWpGaD
Ceftazidime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.000996	0.0154	CbGpPWpGaD
Ceftazidime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.000996	0.0154	CbGpPWpGaD
Ceftazidime—SLC22A5—renal system—prostate cancer	0.000995	0.0614	CbGeAlD
Ceftazidime—SLC22A5—urethra—prostate cancer	0.000978	0.0603	CbGeAlD
Ceftazidime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.000915	0.0141	CbGpPWpGaD
Ceftazidime—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000879	0.0136	CbGpPWpGaD
Ceftazidime—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000816	0.0126	CbGpPWpGaD
Ceftazidime—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.000782	0.0121	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000764	0.0118	CbGpPWpGaD
Ceftazidime—SLC15A2—testis—prostate cancer	0.00074	0.0456	CbGeAlD
Ceftazidime—Skin disorder—Mitoxantrone—prostate cancer	0.000732	0.000798	CcSEcCtD
Ceftazidime—Lethargy—Epirubicin—prostate cancer	0.00073	0.000795	CcSEcCtD
Ceftazidime—Paraesthesia—Estradiol—prostate cancer	0.000726	0.000792	CcSEcCtD
Ceftazidime—Pruritus—Goserelin—prostate cancer	0.000722	0.000787	CcSEcCtD
Ceftazidime—Pruritus—Conjugated Estrogens—prostate cancer	0.000715	0.000779	CcSEcCtD
Ceftazidime—Haemoglobin—Capecitabine—prostate cancer	0.000714	0.000778	CcSEcCtD
Ceftazidime—Haemorrhage—Capecitabine—prostate cancer	0.00071	0.000774	CcSEcCtD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000709	0.0109	CbGpPWpGaD
Ceftazidime—Cefdinir—MPO—prostate cancer	0.000708	0.449	CrCbGaD
Ceftazidime—Hot flush—Doxorubicin—prostate cancer	0.000707	0.000771	CcSEcCtD
Ceftazidime—Hypotension—Mitoxantrone—prostate cancer	0.000704	0.000768	CcSEcCtD
Ceftazidime—Cefaclor—MPO—prostate cancer	0.000702	0.445	CrCbGaD
Ceftazidime—Menopausal symptoms—Doxorubicin—prostate cancer	0.000701	0.000764	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Estradiol—prostate cancer	0.000698	0.000761	CcSEcCtD
Ceftazidime—Diarrhoea—Goserelin—prostate cancer	0.000698	0.000761	CcSEcCtD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000697	0.0108	CbGpPWpGaD
Ceftazidime—Renal impairment—Doxorubicin—prostate cancer	0.000695	0.000758	CcSEcCtD
Ceftazidime—Erythema multiforme—Docetaxel—prostate cancer	0.000693	0.000756	CcSEcCtD
Ceftazidime—Pain—Estradiol—prostate cancer	0.000692	0.000754	CcSEcCtD
Ceftazidime—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000692	0.000754	CcSEcCtD
Ceftazidime—Leukopenia—Etoposide—prostate cancer	0.000688	0.000749	CcSEcCtD
Ceftazidime—Flushing—Docetaxel—prostate cancer	0.000681	0.000742	CcSEcCtD
Ceftazidime—Paraesthesia—Mitoxantrone—prostate cancer	0.000677	0.000738	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—prostate cancer	0.000675	0.000736	CcSEcCtD
Ceftazidime—Dizziness—Goserelin—prostate cancer	0.000675	0.000735	CcSEcCtD
Ceftazidime—Erythema multiforme—Capecitabine—prostate cancer	0.000671	0.000732	CcSEcCtD
Ceftazidime—Dizziness—Conjugated Estrogens—prostate cancer	0.000668	0.000728	CcSEcCtD
Ceftazidime—Convulsion—Etoposide—prostate cancer	0.000666	0.000725	CcSEcCtD
Ceftazidime—Angiopathy—Docetaxel—prostate cancer	0.000665	0.000725	CcSEcCtD
Ceftazidime—Immune system disorder—Docetaxel—prostate cancer	0.000662	0.000722	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Estradiol—prostate cancer	0.000661	0.000721	CcSEcCtD
Ceftazidime—Flushing—Capecitabine—prostate cancer	0.000659	0.000718	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000649	0.000708	CcSEcCtD
Ceftazidime—Vomiting—Goserelin—prostate cancer	0.000649	0.000707	CcSEcCtD
Ceftazidime—Pain—Mitoxantrone—prostate cancer	0.000645	0.000702	CcSEcCtD
Ceftazidime—Angiopathy—Capecitabine—prostate cancer	0.000644	0.000702	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000644	0.000702	CcSEcCtD
Ceftazidime—Rash—Goserelin—prostate cancer	0.000643	0.000701	CcSEcCtD
Ceftazidime—SLC22A5—testis—prostate cancer	0.000643	0.0397	CbGeAlD
Ceftazidime—Dermatitis—Goserelin—prostate cancer	0.000643	0.000701	CcSEcCtD
Ceftazidime—Vomiting—Conjugated Estrogens—prostate cancer	0.000643	0.0007	CcSEcCtD
Ceftazidime—Urticaria—Estradiol—prostate cancer	0.000643	0.0007	CcSEcCtD
Ceftazidime—Immune system disorder—Capecitabine—prostate cancer	0.000641	0.000699	CcSEcCtD
Ceftazidime—Abdominal pain—Estradiol—prostate cancer	0.000639	0.000697	CcSEcCtD
Ceftazidime—Body temperature increased—Estradiol—prostate cancer	0.000639	0.000697	CcSEcCtD
Ceftazidime—Headache—Goserelin—prostate cancer	0.000639	0.000697	CcSEcCtD
Ceftazidime—Rash—Conjugated Estrogens—prostate cancer	0.000637	0.000695	CcSEcCtD
Ceftazidime—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.000637	0.00984	CbGpPWpGaD
Ceftazidime—Dermatitis—Conjugated Estrogens—prostate cancer	0.000637	0.000694	CcSEcCtD
Ceftazidime—Haemoglobin—Prednisone—prostate cancer	0.000636	0.000693	CcSEcCtD
Ceftazidime—Headache—Conjugated Estrogens—prostate cancer	0.000633	0.00069	CcSEcCtD
Ceftazidime—Haemorrhage—Prednisone—prostate cancer	0.000632	0.000689	CcSEcCtD
Ceftazidime—Hallucination—Prednisone—prostate cancer	0.000629	0.000686	CcSEcCtD
Ceftazidime—Anaphylactic shock—Etoposide—prostate cancer	0.000627	0.000683	CcSEcCtD
Ceftazidime—Dysgeusia—Docetaxel—prostate cancer	0.000625	0.000681	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000616	0.000672	CcSEcCtD
Ceftazidime—Thrombocytopenia—Etoposide—prostate cancer	0.000614	0.000669	CcSEcCtD
Ceftazidime—Eosinophilia—Epirubicin—prostate cancer	0.000612	0.000667	CcSEcCtD
Ceftazidime—Skin disorder—Etoposide—prostate cancer	0.000609	0.000664	CcSEcCtD
Ceftazidime—Nausea—Goserelin—prostate cancer	0.000606	0.000661	CcSEcCtD
Ceftazidime—Dysgeusia—Capecitabine—prostate cancer	0.000605	0.00066	CcSEcCtD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000604	0.00933	CbGpPWpGaD
Ceftazidime—Nausea—Conjugated Estrogens—prostate cancer	0.0006	0.000654	CcSEcCtD
Ceftazidime—Urticaria—Mitoxantrone—prostate cancer	0.000599	0.000653	CcSEcCtD
Ceftazidime—Hypersensitivity—Estradiol—prostate cancer	0.000596	0.00065	CcSEcCtD
Ceftazidime—Abdominal pain—Mitoxantrone—prostate cancer	0.000596	0.000649	CcSEcCtD
Ceftazidime—Body temperature increased—Mitoxantrone—prostate cancer	0.000596	0.000649	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000596	0.000649	CcSEcCtD
Ceftazidime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.00059	0.00911	CbGpPWpGaD
Ceftazidime—Flushing—Prednisone—prostate cancer	0.000587	0.00064	CcSEcCtD
Ceftazidime—Pancytopenia—Epirubicin—prostate cancer	0.000587	0.00064	CcSEcCtD
Ceftazidime—Hypotension—Etoposide—prostate cancer	0.000586	0.000639	CcSEcCtD
Ceftazidime—Vision blurred—Capecitabine—prostate cancer	0.000582	0.000635	CcSEcCtD
Ceftazidime—Tremor—Capecitabine—prostate cancer	0.000579	0.000631	CcSEcCtD
Ceftazidime—Neutropenia—Epirubicin—prostate cancer	0.000578	0.00063	CcSEcCtD
Ceftazidime—Angiopathy—Prednisone—prostate cancer	0.000574	0.000625	CcSEcCtD
Ceftazidime—Pruritus—Estradiol—prostate cancer	0.000572	0.000624	CcSEcCtD
Ceftazidime—Leukopenia—Docetaxel—prostate cancer	0.000571	0.000623	CcSEcCtD
Ceftazidime—Immune system disorder—Prednisone—prostate cancer	0.000571	0.000623	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—prostate cancer	0.000566	0.000617	CcSEcCtD
Ceftazidime—Paraesthesia—Etoposide—prostate cancer	0.000563	0.000614	CcSEcCtD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.00056	0.00865	CbGpPWpGaD
Ceftazidime—Hypersensitivity—Mitoxantrone—prostate cancer	0.000555	0.000605	CcSEcCtD
Ceftazidime—Diarrhoea—Estradiol—prostate cancer	0.000553	0.000603	CcSEcCtD
Ceftazidime—Leukopenia—Capecitabine—prostate cancer	0.000553	0.000603	CcSEcCtD
Ceftazidime—Convulsion—Docetaxel—prostate cancer	0.000553	0.000603	CcSEcCtD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000551	0.00851	CbGpPWpGaD
Ceftazidime—Infestation—Epirubicin—prostate cancer	0.000551	0.000601	CcSEcCtD
Ceftazidime—Infestation NOS—Epirubicin—prostate cancer	0.000551	0.000601	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000546	0.000595	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—prostate cancer	0.000543	0.000592	CcSEcCtD
Ceftazidime—Renal failure—Epirubicin—prostate cancer	0.000542	0.00059	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Etoposide—prostate cancer	0.000541	0.00059	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.00054	0.000588	CcSEcCtD
Ceftazidime—Jaundice—Epirubicin—prostate cancer	0.000537	0.000585	CcSEcCtD
Ceftazidime—Pain—Etoposide—prostate cancer	0.000536	0.000584	CcSEcCtD
Ceftazidime—SLC15A2—lymph node—prostate cancer	0.000536	0.033	CbGeAlD
Ceftazidime—Dizziness—Estradiol—prostate cancer	0.000535	0.000583	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—prostate cancer	0.000535	0.000583	CcSEcCtD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000526	0.00813	CbGpPWpGaD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000523	0.00057	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Epirubicin—prostate cancer	0.000521	0.000568	CcSEcCtD
Ceftazidime—Anaphylactic shock—Docetaxel—prostate cancer	0.000521	0.000568	CcSEcCtD
Ceftazidime—Vision blurred—Prednisone—prostate cancer	0.000519	0.000566	CcSEcCtD
Ceftazidime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000518	0.008	CbGpPWpGaD
Ceftazidime—Diarrhoea—Mitoxantrone—prostate cancer	0.000516	0.000562	CcSEcCtD
Ceftazidime—Vomiting—Estradiol—prostate cancer	0.000514	0.000561	CcSEcCtD
Ceftazidime—Agranulocytosis—Epirubicin—prostate cancer	0.000514	0.00056	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Etoposide—prostate cancer	0.000513	0.000559	CcSEcCtD
Ceftazidime—Nervous system disorder—Docetaxel—prostate cancer	0.000511	0.000557	CcSEcCtD
Ceftazidime—Thrombocytopenia—Docetaxel—prostate cancer	0.00051	0.000556	CcSEcCtD
Ceftazidime—Rash—Estradiol—prostate cancer	0.00051	0.000556	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—prostate cancer	0.00051	0.000556	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—prostate cancer	0.00051	0.000556	CcSEcCtD
Ceftazidime—Dermatitis—Estradiol—prostate cancer	0.00051	0.000555	CcSEcCtD
Ceftazidime—Headache—Estradiol—prostate cancer	0.000507	0.000552	CcSEcCtD
Ceftazidime—Skin disorder—Docetaxel—prostate cancer	0.000506	0.000552	CcSEcCtD
Ceftazidime—Agitation—Prednisone—prostate cancer	0.000506	0.000551	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000505	0.000551	CcSEcCtD
Ceftazidime—Angioedema—Prednisone—prostate cancer	0.000503	0.000548	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—prostate cancer	0.000501	0.000546	CcSEcCtD
Ceftazidime—Urticaria—Etoposide—prostate cancer	0.000498	0.000543	CcSEcCtD
Ceftazidime—Haemoglobin—Epirubicin—prostate cancer	0.000497	0.000542	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—prostate cancer	0.000497	0.000542	CcSEcCtD
Ceftazidime—Abdominal pain—Etoposide—prostate cancer	0.000496	0.00054	CcSEcCtD
Ceftazidime—Body temperature increased—Etoposide—prostate cancer	0.000496	0.00054	CcSEcCtD
Ceftazidime—Nervous system disorder—Capecitabine—prostate cancer	0.000495	0.000539	CcSEcCtD
Ceftazidime—Haemorrhage—Epirubicin—prostate cancer	0.000495	0.000539	CcSEcCtD
Ceftazidime—Thrombocytopenia—Capecitabine—prostate cancer	0.000494	0.000538	CcSEcCtD
Ceftazidime—Skin disorder—Capecitabine—prostate cancer	0.00049	0.000534	CcSEcCtD
Ceftazidime—Hypotension—Docetaxel—prostate cancer	0.000487	0.000531	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000482	0.000526	CcSEcCtD
Ceftazidime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.000481	0.00743	CbGpPWpGaD
Ceftazidime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000481	0.00742	CbGpPWpGaD
Ceftazidime—Nausea—Estradiol—prostate cancer	0.00048	0.000524	CcSEcCtD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.00048	0.00741	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.00048	0.00741	CbGpPWpGaD
Ceftazidime—Vomiting—Mitoxantrone—prostate cancer	0.000479	0.000522	CcSEcCtD
Ceftazidime—Convulsion—Prednisone—prostate cancer	0.000477	0.00052	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—prostate cancer	0.000476	0.000519	CcSEcCtD
Ceftazidime—Rash—Mitoxantrone—prostate cancer	0.000475	0.000518	CcSEcCtD
Ceftazidime—Dermatitis—Mitoxantrone—prostate cancer	0.000475	0.000517	CcSEcCtD
Ceftazidime—Headache—Mitoxantrone—prostate cancer	0.000472	0.000515	CcSEcCtD
Ceftazidime—Hypotension—Capecitabine—prostate cancer	0.000471	0.000514	CcSEcCtD
Ceftazidime—Paraesthesia—Docetaxel—prostate cancer	0.000468	0.00051	CcSEcCtD
Ceftazidime—Erythema multiforme—Epirubicin—prostate cancer	0.000468	0.00051	CcSEcCtD
Ceftazidime—SLC22A5—lymph node—prostate cancer	0.000466	0.0287	CbGeAlD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000465	0.000507	CcSEcCtD
Ceftazidime—Hypersensitivity—Etoposide—prostate cancer	0.000462	0.000503	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—prostate cancer	0.00046	0.000501	CcSEcCtD
Ceftazidime—Flushing—Epirubicin—prostate cancer	0.000459	0.0005	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—prostate cancer	0.000458	0.000499	CcSEcCtD
Ceftazidime—Paraesthesia—Capecitabine—prostate cancer	0.000453	0.000494	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Docetaxel—prostate cancer	0.00045	0.00049	CcSEcCtD
Ceftazidime—Anaphylactic shock—Prednisone—prostate cancer	0.000449	0.00049	CcSEcCtD
Ceftazidime—Angiopathy—Epirubicin—prostate cancer	0.000449	0.000489	CcSEcCtD
Ceftazidime—Nausea—Mitoxantrone—prostate cancer	0.000448	0.000488	CcSEcCtD
Ceftazidime—Immune system disorder—Epirubicin—prostate cancer	0.000447	0.000487	CcSEcCtD
Ceftazidime—Pain—Docetaxel—prostate cancer	0.000446	0.000486	CcSEcCtD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000445	0.00688	CbGpPWpGaD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000445	0.00688	CbGpPWpGaD
Ceftazidime—Pruritus—Etoposide—prostate cancer	0.000444	0.000483	CcSEcCtD
Ceftazidime—Nervous system disorder—Prednisone—prostate cancer	0.000441	0.00048	CcSEcCtD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000438	0.00676	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000438	0.00676	CbGpPWpGaD
Ceftazidime—Skin disorder—Prednisone—prostate cancer	0.000436	0.000476	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000435	0.000475	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—prostate cancer	0.000433	0.000472	CcSEcCtD
Ceftazidime—Pain—Capecitabine—prostate cancer	0.000431	0.00047	CcSEcCtD
Ceftazidime—Diarrhoea—Etoposide—prostate cancer	0.000429	0.000468	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Docetaxel—prostate cancer	0.000426	0.000464	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—prostate cancer	0.000425	0.000463	CcSEcCtD
Ceftazidime—Dysgeusia—Epirubicin—prostate cancer	0.000422	0.00046	CcSEcCtD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000416	0.00642	CbGpPWpGaD
Ceftazidime—Angiopathy—Doxorubicin—prostate cancer	0.000415	0.000453	CcSEcCtD
Ceftazidime—Dizziness—Etoposide—prostate cancer	0.000415	0.000452	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—prostate cancer	0.000413	0.000451	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Capecitabine—prostate cancer	0.000412	0.00045	CcSEcCtD
Ceftazidime—Abdominal pain—Docetaxel—prostate cancer	0.000412	0.000449	CcSEcCtD
Ceftazidime—Body temperature increased—Docetaxel—prostate cancer	0.000412	0.000449	CcSEcCtD
Ceftazidime—Vision blurred—Epirubicin—prostate cancer	0.000406	0.000442	CcSEcCtD
Ceftazidime—Paraesthesia—Prednisone—prostate cancer	0.000403	0.00044	CcSEcCtD
Ceftazidime—Urticaria—Capecitabine—prostate cancer	0.000401	0.000437	CcSEcCtD
Ceftazidime—Body temperature increased—Capecitabine—prostate cancer	0.000399	0.000435	CcSEcCtD
Ceftazidime—Abdominal pain—Capecitabine—prostate cancer	0.000399	0.000435	CcSEcCtD
Ceftazidime—Vomiting—Etoposide—prostate cancer	0.000399	0.000434	CcSEcCtD
Ceftazidime—Agitation—Epirubicin—prostate cancer	0.000396	0.000431	CcSEcCtD
Ceftazidime—Rash—Etoposide—prostate cancer	0.000395	0.000431	CcSEcCtD
Ceftazidime—Dermatitis—Etoposide—prostate cancer	0.000395	0.00043	CcSEcCtD
Ceftazidime—Headache—Etoposide—prostate cancer	0.000393	0.000428	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—prostate cancer	0.00039	0.000425	CcSEcCtD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000389	0.00601	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000388	0.00599	CbGpPWpGaD
Ceftazidime—Leukopenia—Epirubicin—prostate cancer	0.000385	0.00042	CcSEcCtD
Ceftazidime—Hypersensitivity—Docetaxel—prostate cancer	0.000384	0.000418	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—prostate cancer	0.000375	0.000409	CcSEcCtD
Ceftazidime—Convulsion—Epirubicin—prostate cancer	0.000373	0.000407	CcSEcCtD
Ceftazidime—Nausea—Etoposide—prostate cancer	0.000372	0.000406	CcSEcCtD
Ceftazidime—Hypersensitivity—Capecitabine—prostate cancer	0.000372	0.000405	CcSEcCtD
Ceftazidime—Pruritus—Docetaxel—prostate cancer	0.000369	0.000402	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Prednisone—prostate cancer	0.000367	0.0004	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—prostate cancer	0.000366	0.000399	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000364	0.000397	CcSEcCtD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000361	0.00558	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.00036	0.00556	CbGpPWpGaD
Ceftazidime—Urticaria—Prednisone—prostate cancer	0.000357	0.000389	CcSEcCtD
Ceftazidime—Pruritus—Capecitabine—prostate cancer	0.000357	0.000389	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—prostate cancer	0.000357	0.000389	CcSEcCtD
Ceftazidime—Diarrhoea—Docetaxel—prostate cancer	0.000356	0.000389	CcSEcCtD
Ceftazidime—Body temperature increased—Prednisone—prostate cancer	0.000355	0.000387	CcSEcCtD
Ceftazidime—Abdominal pain—Prednisone—prostate cancer	0.000355	0.000387	CcSEcCtD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000355	0.00548	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000354	0.00547	CbGpPWpGaD
Ceftazidime—Anaphylactic shock—Epirubicin—prostate cancer	0.000351	0.000383	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—prostate cancer	0.000345	0.000376	CcSEcCtD
Ceftazidime—Diarrhoea—Capecitabine—prostate cancer	0.000345	0.000376	CcSEcCtD
Ceftazidime—Nervous system disorder—Epirubicin—prostate cancer	0.000345	0.000376	CcSEcCtD
Ceftazidime—Dizziness—Docetaxel—prostate cancer	0.000345	0.000376	CcSEcCtD
Ceftazidime—Thrombocytopenia—Epirubicin—prostate cancer	0.000344	0.000375	CcSEcCtD
Ceftazidime—Skin disorder—Epirubicin—prostate cancer	0.000341	0.000372	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000337	0.000367	CcSEcCtD
Ceftazidime—Dizziness—Capecitabine—prostate cancer	0.000334	0.000364	CcSEcCtD
Ceftazidime—Vomiting—Docetaxel—prostate cancer	0.000331	0.000361	CcSEcCtD
Ceftazidime—Hypersensitivity—Prednisone—prostate cancer	0.000331	0.000361	CcSEcCtD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.00033	0.0051	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.00033	0.0051	CbGpPWpGaD
Ceftazidime—Rash—Docetaxel—prostate cancer	0.000328	0.000358	CcSEcCtD
Ceftazidime—Hypotension—Epirubicin—prostate cancer	0.000328	0.000358	CcSEcCtD
Ceftazidime—Dermatitis—Docetaxel—prostate cancer	0.000328	0.000358	CcSEcCtD
Ceftazidime—Headache—Docetaxel—prostate cancer	0.000326	0.000356	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—prostate cancer	0.000325	0.000354	CcSEcCtD
Ceftazidime—Vomiting—Capecitabine—prostate cancer	0.000321	0.00035	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—prostate cancer	0.000319	0.000348	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—prostate cancer	0.000318	0.000347	CcSEcCtD
Ceftazidime—Rash—Capecitabine—prostate cancer	0.000318	0.000347	CcSEcCtD
Ceftazidime—Pruritus—Prednisone—prostate cancer	0.000318	0.000346	CcSEcCtD
Ceftazidime—Dermatitis—Capecitabine—prostate cancer	0.000318	0.000346	CcSEcCtD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000317	0.0049	CbGpPWpGaD
Ceftazidime—Headache—Capecitabine—prostate cancer	0.000316	0.000344	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—prostate cancer	0.000316	0.000344	CcSEcCtD
Ceftazidime—Paraesthesia—Epirubicin—prostate cancer	0.000316	0.000344	CcSEcCtD
Ceftazidime—Nausea—Docetaxel—prostate cancer	0.000309	0.000337	CcSEcCtD
Ceftazidime—Diarrhoea—Prednisone—prostate cancer	0.000307	0.000335	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000307	0.00474	CbGpPWpGaD
Ceftazidime—Hypotension—Doxorubicin—prostate cancer	0.000304	0.000331	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000303	0.000331	CcSEcCtD
Ceftazidime—Pain—Epirubicin—prostate cancer	0.000301	0.000328	CcSEcCtD
Ceftazidime—Nausea—Capecitabine—prostate cancer	0.0003	0.000327	CcSEcCtD
Ceftazidime—Dizziness—Prednisone—prostate cancer	0.000297	0.000324	CcSEcCtD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000294	0.00455	CbGpPWpGaD
Ceftazidime—Paraesthesia—Doxorubicin—prostate cancer	0.000292	0.000318	CcSEcCtD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.00029	0.00447	CbGpPWpGaD
Ceftazidime—Gastrointestinal pain—Epirubicin—prostate cancer	0.000287	0.000313	CcSEcCtD
Ceftazidime—Vomiting—Prednisone—prostate cancer	0.000286	0.000311	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000285	0.0044	CbGpPWpGaD
Ceftazidime—Rash—Prednisone—prostate cancer	0.000283	0.000309	CcSEcCtD
Ceftazidime—Dermatitis—Prednisone—prostate cancer	0.000283	0.000309	CcSEcCtD
Ceftazidime—Headache—Prednisone—prostate cancer	0.000281	0.000307	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000281	0.000306	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.00028	0.00433	CbGpPWpGaD
Ceftazidime—Urticaria—Epirubicin—prostate cancer	0.000279	0.000304	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—prostate cancer	0.000278	0.000303	CcSEcCtD
Ceftazidime—Body temperature increased—Epirubicin—prostate cancer	0.000278	0.000303	CcSEcCtD
Ceftazidime—Abdominal pain—Epirubicin—prostate cancer	0.000278	0.000303	CcSEcCtD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000268	0.00414	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000267	0.00413	CbGpPWpGaD
Ceftazidime—Nausea—Prednisone—prostate cancer	0.000267	0.000291	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000266	0.00029	CcSEcCtD
Ceftazidime—Hypersensitivity—Epirubicin—prostate cancer	0.000259	0.000282	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—prostate cancer	0.000258	0.000282	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—prostate cancer	0.000257	0.00028	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—prostate cancer	0.000257	0.00028	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.00025	0.00386	CbGpPWpGaD
Ceftazidime—Pruritus—Epirubicin—prostate cancer	0.000249	0.000271	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000244	0.00376	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000244	0.00376	CbGpPWpGaD
Ceftazidime—Diarrhoea—Epirubicin—prostate cancer	0.00024	0.000262	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—prostate cancer	0.00024	0.000261	CcSEcCtD
Ceftazidime—Dizziness—Epirubicin—prostate cancer	0.000232	0.000253	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000232	0.00359	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000231	0.00357	CbGpPWpGaD
Ceftazidime—Pruritus—Doxorubicin—prostate cancer	0.00023	0.000251	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000228	0.00353	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000226	0.00349	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000226	0.00349	CbGpPWpGaD
Ceftazidime—Vomiting—Epirubicin—prostate cancer	0.000223	0.000244	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000222	0.00344	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000222	0.00344	CbGpPWpGaD
Ceftazidime—Diarrhoea—Doxorubicin—prostate cancer	0.000222	0.000242	CcSEcCtD
Ceftazidime—Rash—Epirubicin—prostate cancer	0.000222	0.000242	CcSEcCtD
Ceftazidime—Dermatitis—Epirubicin—prostate cancer	0.000221	0.000241	CcSEcCtD
Ceftazidime—Headache—Epirubicin—prostate cancer	0.00022	0.00024	CcSEcCtD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000219	0.00337	CbGpPWpGaD
Ceftazidime—Dizziness—Doxorubicin—prostate cancer	0.000215	0.000234	CcSEcCtD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000215	0.00332	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000211	0.00326	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000211	0.00326	CbGpPWpGaD
Ceftazidime—Nausea—Epirubicin—prostate cancer	0.000209	0.000228	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—prostate cancer	0.000207	0.000225	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—prostate cancer	0.000205	0.000223	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—prostate cancer	0.000205	0.000223	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—prostate cancer	0.000204	0.000222	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000198	0.00305	CbGpPWpGaD
Ceftazidime—Nausea—Doxorubicin—prostate cancer	0.000193	0.000211	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000183	0.00283	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000182	0.00282	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.00018	0.00279	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000172	0.00266	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000169	0.00262	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000168	0.00259	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000168	0.00259	CbGpPWpGaD
Ceftazidime—Cephalexin—CYP3A4—prostate cancer	0.000167	0.106	CrCbGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000167	0.00257	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000161	0.00249	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000159	0.00246	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000153	0.00237	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.00015	0.00231	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000147	0.00227	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000142	0.0022	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—GNG5—prostate cancer	0.00014	0.00216	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000136	0.0021	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000131	0.00202	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000126	0.00194	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000123	0.0019	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000121	0.00187	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000119	0.00184	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000118	0.00182	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000114	0.00177	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000112	0.00174	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000111	0.00171	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000109	0.00169	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000107	0.00166	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000106	0.00163	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000104	0.0016	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—RXRA—prostate cancer	9.88e-05	0.00153	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—NCOA1—prostate cancer	9.64e-05	0.00149	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—NCOA1—prostate cancer	9.48e-05	0.00146	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—RXRA—prostate cancer	9.17e-05	0.00142	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—RXRA—prostate cancer	9.02e-05	0.00139	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—PRKACB—prostate cancer	9e-05	0.00139	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—NCOA2—prostate cancer	8.49e-05	0.00131	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC5A5—prostate cancer	8.1e-05	0.00125	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—PPARA—prostate cancer	7.55e-05	0.00117	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—NCOA1—prostate cancer	7.16e-05	0.00111	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—PPARA—prostate cancer	7e-05	0.00108	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—PPARA—prostate cancer	6.89e-05	0.00106	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—RXRA—prostate cancer	6.81e-05	0.00105	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	5.99e-05	0.000925	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	5.56e-05	0.000859	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—CREBBP—prostate cancer	5.47e-05	0.000845	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—PPARA—prostate cancer	5.2e-05	0.000803	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—CREBBP—prostate cancer	4.13e-05	0.000638	CbGpPWpGaD
